The Analysis of Synergistic Anticancer Effects of Sorafenib and Cynara scolymus Extract on HEPG2 Liver Cancer


Creative Commons License

Kuzucu M.

2 nd Eurasia Biochemical Approaches & Technologies, Antalya, Turkey, 26 - 29 November 2019, pp.162

  • Publication Type: Conference Paper / Summary Text
  • City: Antalya
  • Country: Turkey
  • Page Numbers: pp.162
  • Erzincan Binali Yildirim University Affiliated: Yes

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death in the world, affecting more than 500,000 people. HCC is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis1 . Sorafenib belongs to a group of drugs called protein kinase inhibitors used in the treatment of Hepatocellular carcinoma. This is the first FDA-approved systemic therapy for patients with advanced HCC not amenable to treatment by surgical resection or liver transplantation. Sorafenib is a biaryl urea that blocks the Raf/MEK/ERK pathway by inhibiting Raf serine/threonine kinase isoforms2 . Cynara scolymus (artichokes), widely consumed as part of a traditional Mediterranean diet, yield one such macronutrient, artichoke leaf extract (ALE). Studies have shown that has shown potential as a lipid lowering and hepatoprotective agent. However, the effect of ALE, which is frequently used by liver patients, in the treatment of liver cancer is not yet known3 . In this study, we examined the synergistic effect of Sorafenib and ALE on liver cancer HEPG2 cell. Sorafenib and ALE will be administered separately and in combination to HEPG2 cells and the combination index (CI) values of the results were calculated. Expression levels of some apoptosis genes (Caspase-9, Bax and Bcl-2) will be determined by RT-qPCR at the highest CI. Protein analysis of Caspase-9, Bax and BCL-2 were performed by ELISA. We determined the levels of total antioxidant capacity and the activity of the antioxidant enzymes glutathione peroxidase, glutathione reductase, superoxide dismutase and catalase in the Sorafenib and ALE-applied cells.